296 related articles for article (PubMed ID: 35403792)
21. A Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 Diabetes.
Bassi M; Teliti M; Lezzi M; Iosca A; Strati MF; Carmisciano L; d'Annunzio G; Minuto N; Maggi D
Front Endocrinol (Lausanne); 2021; 12():802419. PubMed ID: 35116007
[TBL] [Abstract][Full Text] [Related]
22. Switching to an advanced hybrid closed-loop system in real-world practice improves hypoglycemia awareness and metabolic control in adults with type 1 diabetes, particularly in those with impaired perception of hypoglycemia symptoms.
Nattero-Chávez L; Lecumberri Pascual E; De La Calle E; Bayona Cebada A; Ruiz T; Quintero Tobar A; Lorenzo M; Sánchez C; Izquierdo A; Luque-Ramírez M; Escobar-Morreale HF
Diabetes Res Clin Pract; 2023 May; 199():110627. PubMed ID: 36940793
[TBL] [Abstract][Full Text] [Related]
23. Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States.
Thrasher JR; Arrieta A; Niu F; Cameron KR; Cordero TL; Shin J; Rhinehart AS; Vigersky RA
Diabetes Technol Ther; 2024 Mar; 26(S3):24-31. PubMed ID: 38377317
[No Abstract] [Full Text] [Related]
24. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
[TBL] [Abstract][Full Text] [Related]
25. Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence.
Choudhary P; Arrieta A; van den Heuvel T; Castañeda J; Smaniotto V; Cohen O
Diabetes Technol Ther; 2024 Mar; 26(S3):32-37. PubMed ID: 38377326
[No Abstract] [Full Text] [Related]
26. Comparison of two advanced hybrid closed loop in a pediatric population with type 1 diabetes: a real-life observational study.
Schiaffini R; Deodati A; Nicoletti MC; Carducci C; Ciampalini P; Lorubbio A; Matteoli MC; Pampanini V; Patera IP; Rapini N; Cianfarani S
Acta Diabetol; 2022 Jul; 59(7):959-964. PubMed ID: 35451679
[TBL] [Abstract][Full Text] [Related]
27. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.
Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R
Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108
[TBL] [Abstract][Full Text] [Related]
28. Real-World User and Clinician Perspective and Experience with MiniMed™ 780G Advanced Hybrid Closed Loop System.
Kesavadev J; Basanth A; Krishnan G; Shankar A; Sanal G; Jothydev S
Diabetes Ther; 2023 Aug; 14(8):1319-1330. PubMed ID: 37278948
[TBL] [Abstract][Full Text] [Related]
29. Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States.
Arunachalum S; Velado K; Vigersky RA; Cordero TL
J Diabetes Sci Technol; 2023 Jul; 17(4):951-958. PubMed ID: 35414272
[TBL] [Abstract][Full Text] [Related]
30. Glycemic control during Ramadan fasting in adolescents and young adults with type 1 diabetes on MiniMed™ 780G advanced hybrid closed‑loop system: A randomized controlled trial.
Elbarbary NS; Ismail EAR
Diabetes Res Clin Pract; 2022 Sep; 191():110045. PubMed ID: 35987309
[TBL] [Abstract][Full Text] [Related]
31. Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics.
Henry Z; Villar Fimbel S; Bendelac N; Perge K; Thivolet C
Diabetes Obes Metab; 2024 Feb; 26(2):557-566. PubMed ID: 37905353
[TBL] [Abstract][Full Text] [Related]
32. Improved technology satisfaction and sleep quality with Medtronic MiniMed® Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial.
Wheeler BJ; Collyns OJ; Meier RA; Betts ZL; Frampton C; Frewen CM; Galland B; Hewapathirana NM; Jones SD; Chan DSH; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; de Bock MI
Acta Diabetol; 2022 Jan; 59(1):31-37. PubMed ID: 34453208
[TBL] [Abstract][Full Text] [Related]
33. The MiniMed 780G automated insulin delivery system adapts to substantial changes in daily routine: Lessons from real world users during Ramadan.
Al-Sofiani ME; Petrovski G; Al Shaikh A; Alguwaihes A; Al Harbi M; Al Mohannadi D; Adjene A; Alagha A; Al Remeithi S; Alamuddin N; Arrieta A; Castañeda J; Chaar W; van den Heuvel T; Cohen O
Diabetes Obes Metab; 2024 Mar; 26(3):937-949. PubMed ID: 38151748
[TBL] [Abstract][Full Text] [Related]
34. Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study.
Matejko B; Juza A; Kieć-Wilk B; Cyranka K; Krzyżowska S; Chen X; Cohen O; Da Silva J; Malecki MT; Klupa T
Diabetes Care; 2022 Nov; 45(11):2628-2635. PubMed ID: 35972259
[TBL] [Abstract][Full Text] [Related]
35. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.
Carlson AL; Sherr JL; Shulman DI; Garg SK; Pop-Busui R; Bode BW; Lilenquist DR; Brazg RL; Kaiserman KB; Kipnes MS; Thrasher JR; Reed JHC; Slover RH; Philis-Tsimikas A; Christiansen M; Grosman B; Roy A; Vella M; Jonkers RAM; Chen X; Shin J; Cordero TL; Lee SW; Rhinehart AS; Vigersky RA
Diabetes Technol Ther; 2022 Mar; 24(3):178-189. PubMed ID: 34694909
[No Abstract] [Full Text] [Related]
36. Clinical Outcomes with MiniMed
Abraham MB; Smith GJ; Dart J; Davis EA; Jones TW
Diabetes Technol Ther; 2024 May; 26(5):341-345. PubMed ID: 38215208
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece.
Lambadiari V; Ozdemir Saltik AZ; de Portu S; Buompensiere MI; Kountouri A; Korakas E; Sharland H; Cohen O
Diabetes Technol Ther; 2022 May; 24(5):316-323. PubMed ID: 34962140
[No Abstract] [Full Text] [Related]
38. Randomised controlled trial of Advanced Hybrid Closed Loop in an Adult Population with Type 1 Diabetes (ADAPT): study protocol and rationale.
de Portu S; Vorrink L; Re R; Shin J; Castaneda J; Habteab A; Cohen O
BMJ Open; 2022 Feb; 12(2):e050635. PubMed ID: 35110310
[TBL] [Abstract][Full Text] [Related]
39. 12-Month Efficacy of Advanced Hybrid Closed-Loop System in Adult Type 1 Diabetes Patients.
Nigi L; Iraci Sareri G; Cataldo D; Dotta F
Diabetes Technol Ther; 2024 Feb; 26(2):130-135. PubMed ID: 37902713
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and Safety of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes Previously Treated with Continuous Subcutaneous Insulin Infusion and Flash Glucose Monitoring.
Gros Herguido N; Amuedo S; Bellido V; López Gallardo G; Losada F; Pérez Morales A; Ruiz Trillo CA; Soto Moreno A
Diabetes Technol Ther; 2023 Feb; 25(2):151-156. PubMed ID: 36108305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
